Incyte Corp. (0J9P) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Incyte Corp. $167, price $115, upside +45.1%, quality 92 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Incyte Corp. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $51.09 – $130.13 · fair‑value band $102.15 – $322.50 · the $115.00 price screens below the $166.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Incyte in your weekly email
Every Wednesday you see whether Incyte is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Show more
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Stock analysis
Incyte Corp. (0J9P) currently trades at $115.00, while our model-based Fair Value estimate is $166.89, implying the stock looks roughly 31.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $280.90 per share, and 16 of the 24 models we run sit above the $115.00 price.
Bear case: the Economic Profit group reads lowest at $53.70, and 8 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $102.15 (bear) to $322.50 (bull), the price of $115.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 92/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Incyte Corp. reported revenue of $5.1B in FY2025 versus $3.0B in FY2021, a compound +14.5%/yr. Reported net income was $1.3B in FY2025, compounding +7.9%/yr from FY2021.
Key figures
Market cap $23.1B · P/E ratio 0.3 · P/S ratio 0.07 · EPS (TTM) $4.20 · Net margin 25.0% · Return on equity 30.8% · Return on assets (EBIT) 10.7% · Operating margin 25.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (medium confidence).
What moves the price
The share trades about 12% below its 52-week high and 37% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 45%, 0J9P screens cheaper than that median.
Fair Value models
Bear $102.15Fair Value $166.89Bull $322.50
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($3.17 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+21.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
Start year 2020 (pandemic). Over 10 years: +21.2% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−6.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.15.2% vs 36.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−9% → 26%
2025 sits 322% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +6.8% a year for the price and +5.1% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 9/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score92 · Top 25%
Fair Value upside+35.7% · Top 25%
Profitability
Return on equity (TTM)30.8% · Top 25%
Return on assets13.9% · Top 25%
Net margin (TTM)26.7% · Top 25%
Operating margin (TTM)25.6% · Top 25%
Growth and dividend
Revenue growth20.9% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Incyte Corp. Fair Value". https://www.fairvalue-calculator.com/stock/0J9P
Frequently asked questions
Is Incyte Corp. (0J9P) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $166.89 versus a price of $115.00, about +45% upside (undervalued).
What is the fair value of 0J9P?
Our model-based fair value for Incyte Corp. is $166.89 (as of Sep 24, 2026), built from audited fundamentals. The current price: $115.00.
What is the quality score of 0J9P?
Incyte Corp. has a Quality Score of 92/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Incyte Corp. (0J9P)?
Our model-based price target is the fair value of $166.89 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $102.15, optimistic scenario $322.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Incyte Corp. stock forecast for 2026?
Our models put fair value at $166.89, about +45% upside versus a price of $115.00 (undervalued). Cautious scenario $102.15, optimistic scenario $322.50. The calculation is refreshed regularly with new filings.
What is the revenue of Incyte Corp. (0J9P)?
Incyte Corp. reported trailing-twelve-month revenue of about $5.4B (latest available figure, as of Sep 24, 2026).
What growth is priced into Incyte Corp. (0J9P)?
For today's price to be fair in a discounted-cash-flow model, Incyte Corp. would have to grow free cash flow by +9.3 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0J9P use?
Our models discount Incyte Corp. at 9.7 %: a base by market capitalisation (unknown), damped by beta 0.76, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Incyte Corp. that is +9.3 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Incyte Corp. (0J9P) delivered so far?
Over the past 5 years revenue at Incyte Corp. grew +14.0 % a year. The price currently implies +9.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Incyte Corp. (0J9P) growing?
The median revenue growth in the sector is +7.2 % a year. That is the yardstick for the growth priced into Incyte Corp. (+9.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Incyte Corp. (0J9P)?
The free-cash-flow yield on the price is 4.43 %: that much free cash flow Incyte Corp. produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Incyte Corp. (0J9P)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Incyte Corp. it is $166.89 per share (as of Sep 24, 2026), against a price of $115.00. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Incyte Corp. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0J9P trades below its calculated fair value: price $115.00, fair value $166.89, a gap of about +45% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0J9P?
No. The price is what the market pays today ($115.00); the fair value is what the company's own numbers justify ($166.89). For Incyte Corp. the two are $51.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Incyte Corp. worth?
The market values Incyte Corp. at about $23.1B (market capitalisation, as of Sep 24, 2026). Per share that is $115.00; our models calculate a fair value of $166.89 per share.
What do the bullish and bearish scenarios say about 0J9P?
Our models span a range for Incyte Corp.: cautious scenario $102.15, base $166.89, optimistic $322.50 per share (as of Sep 24, 2026, price $115.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0J9P?
Incyte Corp. trades at a price-to-earnings ratio of 0.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $166.89 is built from several models across several years.
How solid is the balance sheet of Incyte Corp. (0J9P)?
Balance-sheet figures for Incyte Corp. (as of Sep 24, 2026): return on equity 30.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 92/100, which measures business quality independently of the share price.
How far is 0J9P from its 52-week high?
Incyte Corp. trades at $115.00, about 12% below its 52-week high of $130.13 and 37% above the low of $83.98 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $166.89 is for.
Which stocks are comparable to Incyte Corp.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Incyte Corp. stock attractive at the current price?
The data as of Sep 24, 2026: price $115.00, calculated fair value $166.89 (+45%), Quality Score 92/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0J9P calculated?
We run Incyte Corp. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $166.89, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Incyte Corp. currently trades 31 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Incyte Corp. (0J9P)?
The closing price on Oct 2, 2026 was $115.00. Our model-based fair value is $166.89, about +45% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Incyte Corp. right now?
The rarer combination: high quality (92/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide ($102.15 to $322.50). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Where does the earnings growth of Incyte Corp. (0J9P) come from?
Earnings per share at Incyte Corp. grew +31.7 % a year from 2015 to 2025. Broken into its drivers: revenue per share +18.4 %, EBIT margin +3.8 %, tax rate −4.0 %, residual (interest, one-offs) +11.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Incyte Corp.
How large is the market capitalisation of Incyte Corp. (0J9P)?
The market capitalisation of Incyte Corp. is $23.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Incyte Corp. (0J9P)?
The price-to-sales ratio of Incyte Corp. is 0.07 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Incyte Corp. (0J9P)?
Earnings per share at Incyte Corp. are $4.20 (price ÷ EPS = P/E 0.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Incyte Corp. (0J9P)?
The net margin of Incyte Corp. is 25.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Incyte Corp. (0J9P)?
The return on equity (ROE) of Incyte Corp. is 30.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Incyte Corp. (0J9P)?
On an EBIT basis the return on assets of Incyte Corp. is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Incyte Corp. (0J9P)?
The operating margin of Incyte Corp. is 25.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Incyte Corp. (0J9P)?
Revenue at Incyte Corp. is growing +20.9% versus a year earlier (3y avg +14.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Incyte Corp. (0J9P)?
Earnings per share at Incyte Corp. are growing +83.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Incyte Corp. (0J9P) hold?
Incyte Corp. holds more cash than debt, $3.0B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Incyte Corp. in the live analysis
One click puts Incyte Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
